青光眼患者接受微型分流器植入术失败的危险因素
多中心回顾性队列研究纳入6个青光眼中心的220眼连续病例,采用4种眼压成功标准评估微型分流器植入术的失败危险因素。1年随访时总体成功率43.3%–62.5%,完全成功率35.3%–44.4%。术中丝裂霉素C浓度较高与失败风险降低相关,假性剥脱性青光眼/色素性青光眼、原发性闭角型青光眼及既往非青光眼眼手术为完全成功的失败危险因素。
要点
- 术中丝裂霉素C 0.4 vs 0.2 mg/mL:完全成功HR=0.441(P<.001),总体成功HR=0.360(P=.004)。
- 完全成功的失败危险因素:假性剥脱性/色素性青光眼HR=1.641(P=.004)、原发性闭角型青光眼HR=1.611(P<.001)、既往非青光眼眼手术HR=2.301(P=.002)。
- 总体成功的失败危险因素:术前眼压每升高1 mm Hg HR=0.934(P=.005)、术前抗青光眼药物数量HR=1.626(P<.001)、微型分流器联合白内障手术HR=1.526(P=.033)。
核心结论
- 本研究识别了微型分流器失败的危险因素,强调术中较高丝裂霉素C剂量和仔细选择患者对优化手术成功的重要性。
研究设计与样本
- 多中心回顾性队列研究,纳入6个青光眼中心的220例连续青光眼患者的220眼,均接受微型分流器植入术。
主要发现
- 1年随访时,总体成功率按标准D至标准A为43.3%至62.5%,完全成功率按标准D至标准A为35.3%至44.4%。
- 术中丝裂霉素C浓度较高与完全成功失败风险降低相关(0.4 vs 0.2 mg/mL:HR=0.441,P<.001),也与总体成功失败风险降低相关(0.4 vs 0.2 mg/mL:HR=0.360,P=.004)。
- 完全成功的其他失败危险因素包括假性剥脱性青光眼/色素性青光眼(HR=1.641,P=.004)、原发性闭角型青光眼(HR=1.611,P<.001)和既往非青光眼眼手术(HR=2.301,P=.002)。
- 总体成功的其他失败危险因素包括术前眼压较低(每升高1 mm Hg,HR=0.934,P=.005)、术前抗青光眼药物数量较多(HR=1.626,P<.001)和微型分流器联合白内障手术(HR=1.526,P=.033)。
关键数值与推荐
- 标准A:眼压≤21 mm Hg且眼压降幅≥20%;标准B:眼压≤18 mm Hg且眼压降幅≥20%;标准C:眼压≤15 mm Hg且眼压降幅≥25%;标准D:眼压≤12 mm Hg且眼压降幅≥30%(均相对于基线)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate risk factors for failure of Microshunt in glaucoma patients. DESIGN: Multicenter retrospective cohort study. METHODS: The study included 220 eyes from 220 consecutive glaucoma patients undergoing Microshunt implantation at six glaucoma units. Four intraocular pressure (IOP) success criteria were defined: (A) IOP ≤21 mm Hg with ≥20% IOP reduction; (B) IOP ≤18 mm Hg with ≥20% IOP reduction; (C) IOP ≤15 mm Hg with ≥25% IOP reduction; and (D) IOP ≤12 mm Hg with ≥30% IOP reduction from baseline. Kaplan-Meier analysis was used to estimate success rates according to the criteria above, and multivariable Cox models were used to identified risk factors for failure according to criterion A. RESULTS: Success rates varied based on different criteria, ranging from 43.3% to 62.5% (overall success for criteria D and A, respectively) and from 35.3% to 44.4% (complete success for criteria D and A, respectively) at 1-year follow-up. Higher intraoperative MMC concentration was associated with reduced risk of failure to maintain complete (0.4 vs 0.2 mg/mL: hazard ratio [HR] = 0.441, P < .001) and overall (0.4 vs 0.2 mg/mL: HR = 0.360, P = .004) success. For complete success, other risk factors for failure were pseudoexfoliation glaucoma/pigmentary glaucoma (HR = 1.641, P = .004), primary angle closure glaucoma (HR = 1.611, P < .001), and previous non-glaucomatous ocular surgeries (HR = 2.301, P = .002). For overall success, other risk factors for failure were lower preoperative IOP (for 1-mm Hg increase, HR = 0.934, P = .005), higher number of preoperative antiglaucoma agents (HR = 1.626, P < .001), and Microshunt combined with cataract surgery (HR = 1.526, P = .033). CONCLUSIONS: This study identified risk factors for Microshunt failure, highlighting the importance of high intraoperative MMC dose and careful patient selection to optimize surgical success.
引用
- Rabiolo A, Toscani R, Sacchi M, et al. Risk Factors for Failure in Glaucoma Patients Undergoing Microshunt Implantation. Am J Ophthalmol. 2023. PMID: 37979601. doi:10.1016/j.ajo.2023.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。